Broken String Biosciences launches catalyst program

The offering can be integrated into early therapeutics development at target validation, reducing risk and removing the need for costly internal workflows that slow development progress. It is cell and nuclease agnostic, enabling direct measurementin clinically relevant samples, addressing regulatory scrutiny around unintended edits.

The gene editing industry has reached an inflection point, where the momentum required to reach its potential can only be sustained by expanding patient access – which requires standardization, faster drug development, and robust safety characterization. Our Catalyst program will enable faster and broader industry-wide adoption of INDUCE-seq® and position this as an essential technology for the next wave of gene-editing based therapeutics.”

Felix Dobbs, co-founder and CEO of Broken String Biosciences

Through the harmonization of complex datasets from various sources, Rancho ensures that DISQOVER users can delve deeply into their data, uncovering insights that might otherwise remain hidden. By leveraging DISQOVER’s data linking capabilities, user-friendly interface, and GenAI functionality, this collaboration generates reliable, actionable insights that are crucial for today's AI and ML-driven research.

For years, companies have been using INDUCE-seq® via Broken String’s labs to ensure safety before entering clinical trials. INDUCE-seq® solves a fundamental safety challenge that dates back to the origins of gene editing: how to assess on- and off-target effects as they happen. By making the same technology available for developers in their own labs, they retain full control over their experiments while incorporating safety throughout the entire development process.

The industry lacks a gold standard for detecting on- and off-target edits. Current approaches can have PCR-induced bias, and miss low-frequency unintended edits that are potentially dangerous and can have disastrous consequences for clinical programs. INDUCE-seq® improves on existing technologies by delivering unbiased genome-wide insights, accurately detecting double-strand DNA breaks from CRISPR and other gene editing technologies.

‍Broken String’s on-premise Catalyst EAP accelerates discovery programs with iterative use to screen guide RNAs based on efficacy, as measured through on-target editing efficiency, as well as also providing quick indications for off-target safety. Enrollment in the Catalyst EAP is limited to a select group of participants.

Visit https://www.brokenstringbio.com/resources/catalyst-program/ to learn more and apply.